2 results match your criteria: "Bellvitge University Hospital-Bellvitge Institute of Biomedical Research (IDIBELL)[Affiliation]"
Tuberculosis prevention in patients undergoing kidney transplantation: A nurse-led program for screening and treatment.
Transpl Infect Dis
August 2021
Tuberculosis Unit, Service of Infectious Diseases, Bellvitge University Hospital-Bellvitge Institute of Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Spain.
Background: Systematic screening for, and treatment of, latent tuberculosis (TB) infection is recommended prior to kidney transplant. However, little is known about patient compliance with, or the safety profile of, preventive therapies used in clinical practice.
Methods: This was a retrospective observational study of patients who were eligible for kidney transplant and were evaluated for TB infection between January 2013 and June 2019 at the TB clinic of a tertiary care teaching hospital.
Rifabutin for treating tuberculosis in solid organ transplant recipients: A retrospective observational study and literature review.
Transpl Infect Dis
April 2021
Department of Infectious Diseases and Tuberculosis Unit, Bellvitge University Hospital-Bellvitge Institute of Biomedical Research (IDIBELL), Barcelona, Spain.
Background: The treatment of tuberculosis (TB) in solid organ transplant (SOT) recipients is challenging owing to interactions between rifampin and immunosuppressive drugs. Rifabutin, a rifamycin with excellent activity against Mycobacterium tuberculosis and that induces cytochrome p450 less, may facilitate treatment. We report our experience with rifabutin for treating TB in SOT recipients and review the available literature.
View Article and Find Full Text PDF